favezelimab

News

End of the line for MSD's TIGIT, LAG-3 cancer drugs

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

News

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

News

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co.

End of the line for MSD's TIGIT, LAG-3 cancer drugs

MSD hits a hurdle with its LAG-3 programme

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

On AI and computational support of biochemistry, with Alan R...

The AI imperative: Establishing the standard for modern clin...

Editor's Picks